A novel prognostic gene expression risk score, including the expression of CCL5, CTNNB1, EXOSC3, LZTR1, and clinical parameters, was recently established and validated for perioperative chemotherapy treatment of GC [102]. This evidence concerns the gene CCL5 and gastric cancer.